Boehringer Ingelheim Exits HCV Space
By: Marcus Hopkins, Blogger
Weve spoken several times about the new HCV medications making their
ways into the marketplace, but what happens when one of these new treatments
simply doesnt pan out for the company that manufactures them?
This question was recently answer, by Boehringer Ingelheim (BI), who, in
a statement released on June 18th, have decided not to move forward with
any approvals or market considerations for their HCV protease inhibitor,
CLICK HERE to read: Boehringer Ingelheim Exits HCV
Black Market HIV/AIDS Drugs in the News, 2006 - 2013
The Partnership for Safe Medicines
The Community Access National Network (CANN) today announced that it is teaming
up with the Partnership for Safe Medicines (PSM) to better educate patients
about the risks of counterfeit or black market HIV/AIDS medicines. Since
2006, eighty-two (82) individuals have been charged with selling adulterated,
unapproved or black market medications prescribed for HIV or AIDS patients.
HERE to download, "Black Market HIV/AIDS Drugs in the News, 2006 - 2013"